1
|
Kwon N, Lee RT, Ray M, Szmulewitz RZ, Von Roenn JH, Stadler WM, Curlin FC. The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Rosenbloom SK, Beaumont J, Diaz P, Yount SE, Abernethy AP, Jacobsen PB, Paul D, Syrjala K, Von Roenn JH, Cella D. Patient-centered validation of 11 symptom indices to evaluate response to chemotherapy for advanced cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6524 Background: Symptom burden in advanced disease has relevance both for clinical practice and in evaluating the efficacy of new chemotherapeutic agents. This study aimed to identify patients’ highest priority symptoms for 11 advanced cancers, compare priority ratings with those obtained from clinicians, and construct brief symptom indices based on their combined input. Methods: 534 patients with advanced bladder, brain, breast, colorectal, head/neck, hepatobiliary/pancreatic, kidney, lung, lymphoma, ovarian or prostate cancer from a subset of National Comprehensive Cancer Network (NCCN) member institutions and 4 Cancer Health Alliance of Metropolitan Chicago organizations completed a survey of priority symptoms and concerns and a disease-specific FACT QOL measure. 112 physicians at NCCN institutions completed a rating of whether symptoms and concerns were considered disease- or treatment-related. Symptoms endorsed more often than chance probability were retained. Expert clinician and patient ratings were equally weighted in item selection. Responses to symptom index items drawn from the QOL questionnaires allowed for validation analyses. Results: Items comprising 2 to 3 subscales (up to 20 items in length) were retained for each of the 11 disease-specific symptom indices. Content-determined subscales consisted of symptoms and concerns that were 1) exclusively or predominantly disease-related symptoms (DRS); 2) exclusively or predominantly treatment side effects (TSE); and 3) descriptive of general function or well-being (F/WB). For example, the NCCN/FACT Breast Cancer Symptom Index (FBSI) contains 17 items: 8 DRS, 4 TSE and 5 F/WB. Data on 14 of 17 FBSI items showed good internal consistency (a=.89). Correlations between FBSI and FACT-B scores were high for physical well-being, functional well-being and breast cancer subscales (r = 0.83, 0.77, and 0.61 respectively). Correlation with emotional well-being subscale was 0.55. FBSI scores differed across PSR groups in the appropriate direction (p<0.0001). Conclusions: NCCN/FACT disease-specific questionnaires have been transformed into brief, patient-centered symptom indices that can be used as stand-alone measures in oncology research and practice. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. K. Rosenbloom
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - J. Beaumont
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - P. Diaz
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - S. E. Yount
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - A. P. Abernethy
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - P. B. Jacobsen
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - D. Paul
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - K. Syrjala
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - J. H. Von Roenn
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| | - D. Cella
- Evanston Northwestern Healthcare, Evanston, IL; Duke University Medical Center, Durham, NC; University of South Florida Moffitt Cancer Center, Tampa, FL; National Comprehensive Cancer Network, Jenkintown, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Northwestern Univ Med/RHLCCC, Chicago, IL
| |
Collapse
|
3
|
Von Roenn JH, Lee S, Cianfrocca M, Tulpule A, Scadden D, Aboulafia D, Sparano J. Phase III study of paclitaxel (Pac) versus pegylated liposomal doxorubicin (PLD) for the treatment of advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS): An Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.20503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20503 Background: PLD (doxorubicin HCL liposome injection, Doxil®, Tibotec Therapeutics, Raritan, NJ) and paclitaxel (Taxol®, Bristol Myers, Inc, New York, NY) are active in the treatment of HIV-associated KS; however, optimal therapy is undefined. Methods: A randomized phase III, multicenter trial was initiated to compare the efficacy of Pac (100 mg/m2) every 2 weeks to PLD (20 mg/m2) every 3 weeks for chemotherapy-naïve AIDS-related KS. Treatment continued until disease progression or unacceptable toxicity; concurrent antiretrovirals were permitted. 216 pts were required to detect at least a 3-month improvement in median progression free survival (PFS) for Pac compared with PLD (80% power, 2-sided alpha 0.05). Response was assessed using KS response and clinical benefit criteria, and global assessment of quality of life (QOL) using the Functional Assessment of Health Index (FAHI; version 3) plus 3 supplemental questions concerning pain, swelling, and satisfaction with physical appearance (measured at baseline and during/after treatment). Results: The trial was terminated early due to poor accrual; 46 pts were randomized to PLD, 43 to Pac. 11 pts were ineligible, 4 never started therapy and 6 lacked disease assessment or progression data, resulting in 68 pts for the efficacy analysis (34 in each arm) and 82 in the toxicity analysis. After a median follow-up of 35.8 months (mo.), there was no significant difference in PFS, response rate, or overall survival. Due to early termination, the study was not adequately powered to detect the hypothesized difference in PFS. There was no significant difference in QOL between the two arms. Grade 3–4 toxicity was comparable, including grade 4 neutropenia (34% vs. 27%) and infection (13% vs. 11%). Conclusions: Paclitaxel and PLD have comparable efficacy and toxicity in patients with HIV-associated KS. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- J. H. Von Roenn
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - S. Lee
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - M. Cianfrocca
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - A. Tulpule
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - D. Scadden
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - D. Aboulafia
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| | - J. Sparano
- Northwestern Univ, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Southern California, Los Angeles, CA; Massachusetts General Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA; Montefiore Medical Center, Bronx, NY
| |
Collapse
|
4
|
|
5
|
Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res 2001; 104:127-48. [PMID: 11191125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- J H Von Roenn
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fox Chase Cancer Center, USA
| | | |
Collapse
|
6
|
Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 1999; 21 Suppl 1:S31-3. [PMID: 10430216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Combination therapy with protease inhibitors and nucleoside analogues dramatically suppresses plasma HIV-1 RNA and delays progression to AIDS, but the impact on HIV-associated malignancy remains to be established. We therefore examined incidence trends of Kaposi's sarcoma and non-Hodgkin's lymphoma in patients with advanced HIV infection in nine AIDS Clinical Trial Group studies of antiviral therapies for HIV and cytomegalovirus infections. Among a total of 6587 patients enrolled between November 1987 and February 1997, there were 280 cases of Kaposi's sarcoma and 68 cases of non-Hodgkin's lymphoma. Incidence rates per 100 person-years of both malignancies declined in concert with decreases in mortality, but the decreases in Kaposi's sarcoma were more profound and consistent than the decreases in non-Hodgkin's lymphoma. These data suggest that current therapies have ameliorated the incidence of Kaposi's sarcoma, but may not have had an equal effect on non-Hodgkin's lymphoma.
Collapse
Affiliation(s)
- C S Rabkin
- Viral Epidemiology Branch, National Cancer Institute, Bethesda, Maryland, USA
| | | | | | | |
Collapse
|
7
|
Lothian ST, Fotis MA, von Gunten CF, Lyons J, Von Roenn JH, Weitzman SA. Cancer pain management through a pharmacist-based analgesic dosing service. Am J Health Syst Pharm 1999; 56:1119-25. [PMID: 10385460 DOI: 10.1093/ajhp/56.11.1119] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S T Lothian
- Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL 60611, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- M D Volm
- Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
| | | |
Collapse
|
9
|
Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16:1444-9. [PMID: 9552050 DOI: 10.1200/jco.1998.16.4.1444] [Citation(s) in RCA: 100] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PURPOSE Angiogenesis is a major component of Kaposi's sarcoma (KS) and a critical process in tumor growth. The present study was designed primarily to test the toxicity and pharmacokinetics (PK) of the angiogenesis inhibitor TNP-470 and secondarily to evaluate tumor response in patients with early AIDS-related KS. PATIENTS AND METHODS Patients with AIDS-related KS were required to have cutaneous disease with > or = 5 measurable lesions and no evidence of pulmonary, symptomatic gastrointestinal, or acutely life-threatening KS. Thirty-eight patients received TNP-470 by weekly intravenous infusion over 1 hour at one of six dose levels for up to 24 weeks. RESULTS The dose levels tested included 10, 20, 30, 40, 50 and 70 mg/m2. Median CD4 count was 24 cells/microl (range, 0 to 460). Fourteen patients (36%) had > or = 50 cutaneous lesions and 19 (49%) had oral lesions. Adverse events included neutropenia (n = 2), hemorrhage (n = 3), and urticaria (n = 1). PK studies showed wide interpatient and intrapatient variability. Elimination half-life values were short (range, 0.01 to 0.61 hours). Seven patients (18%) achieved a partial response. The median time to partial response was 4 weeks (range, 2 to 25), and the median duration of response was 11 weeks (range, 3 to 26+). CONCLUSION TNP-470, administered as a weekly, 1-hour infusion to patients with early AIDS-KS is well-tolerated at doses up to and including the highest dose tested. Tumor responses were observed in a substantial number of cases and occurred at various dose levels. TNP-470 should be evaluated further in patients with AIDS-KS as a single agent and in combination with other biologic response modifiers in early disease or after initial response to cytotoxic chemotherapy.
Collapse
Affiliation(s)
- B J Dezube
- Beth Israel Deaconess Medical Center, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Von Roenn JH, Krown SE. Management of AIDS-associated Kaposi's sarcoma: a multidisciplinary perspective. Oncology (Williston Park) 1998; 12:1-24. [PMID: 9524965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
11
|
Affiliation(s)
- M Cianfrocca
- Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
| | | |
Collapse
|
12
|
Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15:653-9. [PMID: 9053490 DOI: 10.1200/jco.1997.15.2.653] [Citation(s) in RCA: 129] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE To determine the efficacy and safety of pegylated-liposomal doxorubicin in patients with AIDS and Kaposi's sarcoma (AIDS-KS) who experienced failure of standard chemotherapy. METHODS Fifty-three patients with advanced AIDS-KS who experienced disease progression or intolerable toxicities while receiving standard doxorubicin/bleomycin/vincristine (ABV) or bleomycin/vincristine (BV) chemotherapy were identified from a cohort of patients who were then treated with pegylated-liposomal doxorubicin. Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, Inc, Menlo Park, CA) every 3 weeks. RESULTS Nineteen patients (36%) had a partial response (PR) and one patient had a clinical complete response (CCR). The median duration of response and time (from study entry) to treatment failure were 128 and 134 days, respectively. Of 28 patients who experienced disease progression while receiving combination regimens that contained standard doxorubicin, the PR rate was 32%, which suggests that the pegylated-liposomal encapsulation increases the therapeutic effect of doxorubicin. Patients obtained clinical benefits such as flattening of lesions (48%), improved lesion color (56%), relief of pain (45%), and loss of edema (83%). Forty-nine percent of patients had more than one clinical benefit. The most common adverse effect was leukopenia, which occurred in 40% of patients. Only 15% of patients had nausea and/or vomiting, none of which was severe; 9% experienced alopecia, also generally mild. CONCLUSION Pegylated-liposomal doxorubicin offers a new alternative for treatment of patients who have experienced failure of standard chemotherapy for AIDS-KS.
Collapse
|
13
|
Abstract
HIV-infected individuals are at an increased risk for development of cancers other than the three AIDS-defining malignancies. Two non-AIDS-defining cancers, germ cell tumors and Hodgkin's disease, have been reported in the setting of HIV infection with increased frequency compared with their incidence in the general population. Other non-AIDS-defining malignancies frequently reported in the setting of HIV infection include lung cancer, squamous and basal cell carcinomas of the skin, anal carcinoma, and pediatric leiomyosarcomas.
Collapse
Affiliation(s)
- M D Volm
- Division of Oncology, Bellevue Hospital, New York, NY 10016, USA
| | | |
Collapse
|
14
|
Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology (Williston Park) 1996; 10:1049-56; discussion 1062-4, 1067-8. [PMID: 8837121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Early intervention and attention to nutritional status are essential in patients with cachexia. Identification of reversible causes of decreased energy intake and/or weight loss is the first step in treatment. When such factors cannot be identified, pharmacologic interventions should be considered. To date, megestrol acetate is the most effective appetite stimulant. Appetite and weight gain occur to a greater and more rapid degree as megestrol dose increases. Unfortunately, the weight gain is due predominantly to an increase in fat mass. Whether this is due to a lack of exercise in the face of increased caloric intake and/or to the hypogonadal effects of megestrol acetate is being tested in ongoing clinical trials. Anabolic agents, particularly growth hormone, are exciting potential therapies. No data are yet available on alternate doses and schedules of growth hormone or on its effect in patients with decreased oral intake. Current studies addressing combination therapy with anabolic agents and appetite stimulants should clarify their respective therapeutic roles.
Collapse
|
15
|
von Gunten CF, Von Roenn JH, Johnson-Neely K, Martinez J, Weitzman S. Hospice and palliative care: attitudes and practices of the physician faculty of an academic hospital. Am J Hosp Palliat Care 1995; 12:38-42. [PMID: 7543273 DOI: 10.1177/104990919501200413] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
It has been suggested that physicians, particularly in academic hospitals, are resistant to the hospice approach to palliative care for terminally ill patients. It is of interest, therefore, to assess the attitudes and practices of the physician faculty of an academic hospital where a hospice program has been in existence for more than 10 years. This was assessed with two faculty surveys. All 966 physician faculty that were on staff at Northwestern Memorial Hospital in the fall of 1993 were sent a survey about their opinion of hospice care (Survey A). Then, all physicians who had referred patients to the hospice program between September 1993 and September 1994 at Northwestern Memorial Hospital received a survey letter after the death of their patient (Survey B). Seventy-seven percent of faculty physician respondents to Survey A had either referred patients, or knew of colleagues who had referred patients to a hospice program. Ninety-four percent of those who answered "yes" to the question about referrals reported satisfaction with their care. Ninety-four percent would refer patients in the future and 96 percent thought the hospice program was a valuable resource to the medical center. Of the respondents to Survey B, nearly 100 percent thought the referral had been handled in an "excellent" or "good" fashion, that communication with hospice staff was "excellent" or "good," that symptom control was "excellent" or "good," that their patients and families had received "excellent" or "good" psychosocial support, and that their patients and families were satisfied with the hospice care they received.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
16
|
Von Gunten CF, Von Roenn JH, Gradishar W, Weitzman S. A hospice/palliative medicine rotation for fellows training in hematology-oncology. J Cancer Educ 1995; 10:200-202. [PMID: 8924394 DOI: 10.1080/08858199509528373] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
A clinical hospice/palliative medicine rotation for physicians enrolled in a three-year hematology/oncology fellowship was established in academic year 1993-1994 as a way to accomplish important training goals in pain management and the palliative care of patients with terminal illness. This study was conducted to obtain initial information about its effectiveness. Ten fellows, one at a time, evaluated new hospice/palliative medicine consultations, supervised the care of patients on an inpatient hospice/palliative care unit, and visited patients at home. For the first 13 months, seven fellows were assigned to this rotation for one month each, and three fellows were assigned to spend two separate months each. A self-report evaluation of the experience was administered at the end of each service month. In five of these 13 evaluations, the fellows reported their skills in managing pain and symptoms to be much improved, and in eight they indicated their skills were improved; none stated that there had been no change. Comfort and skill with discussing death, dying, and advanced directives with patients and families were reported by the fellows to be much improved in nine evaluations, improved in three, and unchanged in one. In nine evaluations, the fellows reported their understanding of hospice/palliative care as a program and approach to patient care was much improved; in two, improved; and in two, unchanged. All of the fellows would recommend this rotation to other fellows. A clinical rotation in palliative medicine and hospice care is a useful addition to the curriculum of fellows training in hematology-oncology.
Collapse
Affiliation(s)
- C F Von Gunten
- Hematology/Oncology, Northwestern University Medical School, Chicago, IL 60611, USA
| | | | | | | |
Collapse
|
17
|
Abstract
Involuntary weight loss is a frequent complication of acquired immune deficiency syndrome (AIDS) and ultimately affects the majority of patients. The deleterious effects of weight loss on immune function and the physical and psychological sequelae of severe weight loss are well recognized. Megestrol acetate induces appetite stimulation and nonfluid weight gain in patients with advanced hormone nonresponsive cancers. In a pilot study, megestrol acetate produced nonfluid weight gain in patients with AIDS. Two double-blind randomized placebo-controlled trials of megestrol acetate for the treatment of AIDS-related anorexia and cachexia have shown improvements in body weight with treatment. In a multicenter trial reported by Flynn et al. at the 7th International Conference on AIDS (1992), 65 patients with AIDS and weight loss of > 10% of ideal body weight were randomized to placebo or megestrol acetate 800 mg/day. Megestrol acetate-treated patients had a significantly greater mean maximum weight gain (p = 0.027) and appetite stimulation (p = 0.021) than did placebo-treated patients. In a second, larger randomized placebo-controlled trial, 271 patients with AIDS, anorexia and cachexia were randomized to receive placebo or multiple doses of megestrol acetate at 100, 400 or 800 mg/day for 12 weeks. A maximum weight gain of at least 5 lb (2.25 kg) was observed in 64.2% of patients in the 800-mg megestrol acetate group compared with 21.4% in the placebo group (p < 0.0001). Mean maximum weight change from baseline to last evaluation was +8.3 lb in the 800-mg group and -1.1 lb in the placebo group (p < 0.001). Mean change in lean body mass from baseline to last evaluation was +2.5 lb in the 800-mg group versus -1.7 lb in the placebo group (p < 0.001). A significant improvement in appetite was seen in patients receiving 800 mg megestrol acetate compared with patients receiving placebo. No significant toxicity was observed with megestrol acetate therapy. Megestrol acetate is an effective treatment for some patients with AIDS-related anorexia and cachexia.
Collapse
Affiliation(s)
- J H Von Roenn
- Department of Internal Medicine, Northwestern University, Chicago, IL 60611
| |
Collapse
|
18
|
Abstract
OBJECTIVES To compare the effects of oral suspensions of megestrol acetate, 800 mg/d, and placebo on body weight in patients with acquired immunodeficiency syndrome (AIDS)-related weight loss. DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Outpatient community and university patient care setting. PATIENTS Consecutive patients with AIDS who had substantial weight loss and anorexia were enrolled. Of 271 patients, 270 and 195 were evaluable for safety and efficacy, respectively. INTERVENTIONS Patients were randomly assigned to receive placebo or megestrol acetate (100 mg, 400 mg, or 800 mg) daily for 12 weeks. MAIN OUTCOME MEASURES The primary efficacy criterion was weight gain. Patients were evaluated at 4-week intervals for changes in weight and body composition, caloric intake, sense of well-being, toxic effects, and appetite. RESULTS For evaluable patients receiving 800 mg of megestrol acetate per day, 64.2% gained 2.27 kg (5 pounds) or more compared with 21.4% of patients receiving placebo (P < 0.001). An intent-to-treat analysis showed significant differences (P = 0.002) between those receiving placebo and those receiving 800 mg of megestrol acetate for the number of patients who gained 2.27 kg (5 pounds) or more (8 of 32 [25%] compared with 38 of 61 [62.3%], respectively). Compared with patients receiving placebo at the time of maximum weight change, evaluable patients receiving megestrol acetate, 800 mg/d, reported improvement in overall well-being and had an increase in mean weight gain (-0.725 compared with 3.54 kg [-1.6 compared with +7.8 pounds]; P < 0.001), lean body mass (-0.772 compared with +1.14 kg [-1.7 compared with +2.5 pounds]; P < 0.001), appetite grade (P < 0.001), and caloric intake (-107 compared with +645.6 calories/d; P = 0.001). CONCLUSIONS In patients with AIDS-related weight loss, megestrol acetate can stimulate appetite, food intake, and statistically significant weight gain that is associated with a patient-reported improvement in an overall sense of well-being.
Collapse
|
19
|
Abstract
Involuntary bodyweight loss is a frequent manifestation of HIV infection and ultimately affects the majority of patients. Because it portends a poor prognosis and adversely affects quality of life, nutritional intervention has an important role in the care of all HIV-infected persons. The mechanism of HIV-related bodyweight loss is multifactorial and includes complex interactions between decreased caloric intake, malabsorption and metabolic and/or hormonal abnormalities. Treatment of reversible and identifiable causes of bodyweight loss such as opportunistic infections and adverse effects of therapy are essential for the maintenance of bodyweight. For patients with anorexia of unclear aetiology, there are effective appetite stimulants available. Enteral and parenteral alimentation are under evaluation for their role in maintenance and/or repletion of bodyweight for patients with HIV infection.
Collapse
Affiliation(s)
- J H Von Roenn
- Northwestern University Medical School, Chicago, Illinois
| |
Collapse
|
20
|
Abstract
The authors report three cases of Raynaud phenomenon that developed during doxorubicin, bleomycin, and vincristine (ABV) therapy for acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma. Although Raynaud phenomenon is well documented as a side effect of bleomycin, vinblastine, and cisplatin chemotherapy for germ cell neoplasms, it has not been widely documented in patients with AIDS.
Collapse
|
21
|
Abstract
OBJECTIVE The Eastern Cooperative Oncology Group (ECOG) conducted a groupwide survey to determine the amount of knowledge about cancer pain and its treatment among physicians practicing in ECOG-affiliated institutions and to determine the methods of pain control being used by these physicians. DESIGN Survey. SETTING A questionnaire was sent to all ECOG physicians with patient care responsibilities (medical oncologists, hematologists, surgeons, and radiation therapists), practicing in university institutions, Community Clinical Oncology Program (CCOP) institutions, and Cooperative Group Outreach Programs (CGOP) institutions. MEASUREMENTS A physician cancer pain questionnaire developed by the Pain Research Group at the University of Wisconsin was used. The questionnaire was designed to assess physicians' estimates of the magnitude of pain as a specific problem for cancer patients, their perceptions of the adequacy of cancer pain management, and their report of how they manage pain in their own practice setting. RESULTS The study analyzed responses to 897 of 1800 surveys. In regard to the use of analgesics for cancer pain in the United States, 86% felt that the majority of patients with pain were undermedicated. Only 51% believed pain control in their own practice setting was good or very good; 31% would wait until the patient's prognosis was 6 months or less before they would start maximal analgesia. Adjuvants and prophylactic side-effect management should have been used more frequently in the treatment plan. Concerns about side-effect management and tolerance were reported as limiting analgesic prescribing. Poor pain assessment was rated by 76% of physicians as the single most important barrier to adequate pain management. Other barriers included patient reluctance to report pain and patient reluctance to take analgesics (both by 62%) as well as physician reluctance to prescribe opioids (61%). CONCLUSIONS Professional education needs to focus on the proper assessment of pain, focus on the management of side effects, and focus on the use of adjuvant medications. A better understanding of the pharmacology of opioid analgesics is also needed. Physicians also need to educate patients to report pain and to effectively use the medications that are prescribed for pain management.
Collapse
Affiliation(s)
- J H Von Roenn
- Northwestern University Medical School, Section of Medical Oncology, Chicago, IL 60611
| | | | | | | | | |
Collapse
|
22
|
Abstract
As patients with human immunodeficiency virus infection live longer because of better antiretroviral therapy and infection prophylaxis, the incidence of non-Hodgkin's lymphoma has increased. The risk increases inversely with CD4 count--the most widely used surrogate marker for progressive immune suppression. Zidovudine itself does not appear to be a risk factor. Patients frequently present with extranodal advanced disease. The central nervous system is the primary site in 10% to 20% of cases. Important prognostic factors are performance status, a prior history of acquired immunodeficiency syndrome, and bone marrow involvement. Therapy is complicated by underlying immunosuppression, opportunistic infection, and poor bone marrow reserve. Progress has been made using colony-stimulating factors and less intensive chemotherapy regimens in systemic non-Hodgkin's lymphoma. Treatment of primary central nervous system lymphoma with radiation therapy has not improved survival.
Collapse
|
23
|
Abstract
Involuntary weight loss or wasting indicative of severe protein energy malnutrition is a frequent complication of acquired immune deficiency syndrome (AIDS). Malnutrition, with its associated adverse effects on immunocompetence, may contribute to the progression of AIDS itself. Since death from wasting is ultimately related to the magnitude of tissue depletion, restoration of body cell mass may enhance survival. The mechanism of weight loss in AIDS has not been clearly elucidated. The etiology is likely to be multifactorial, the result of interactions between decreased caloric intake, malabsorption, and alterations in energy expenditure secondary to hormonal and/or metabolic abnormalities. Although weight loss is occasionally reversible with treatment of underlying infections and/or easily identifiable and reversible causes, the majority of patients are not this fortunate. Enteral and parenteral nutrition, which are expensive, cumbersome, and potentially morbid, have been suggested by some as therapeutic options. Megestrol acetate, a synthetic, orally active progestational agent, has been reported to stimulate appetite and weight gain. Data regarding the use of megestrol acetate for the treatment of cachexia related to human immunodeficiency virus (HIV) infection demonstrate convincingly its effectiveness in treating many patients with HIV-related anorexia and cachexia.
Collapse
Affiliation(s)
- J H Von Roenn
- Department of Medicine, Northwestern University Medical School, Chicago, Ill
| | | | | |
Collapse
|
24
|
McDunn SH, Winter JN, Variakojis D, Rademaker AW, Von Roenn JH, Tallman MS, Gordon LI, Bauer KD. Human immunodeficiency virus-related lymphomas: a possible association between tumor proliferation, lack of ploidy anomalies, and immune deficiency. J Clin Oncol 1991; 9:1334-40. [PMID: 1677032 DOI: 10.1200/jco.1991.9.8.1334] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
In an attempt to identify a biologic basis for the aggressive clinical behavior of human immunodeficiency virus (HIV)-associated lymphomas (HAL), dual-parameter flow-cytometric analysis was performed on 22 paraffin-embedded biopsy specimens. Cases were analyzed for DNA ploidy, the percentage of cells in S-phase (proliferative activity), and content of a recently identified proliferation-associated nuclear antigen, p105. The DNA-content analysis of 22 HALs was compared with that of 109 cases of intermediate-grade non-Hodgkin's lymphoma (NHL) unrelated to the acquired immune deficiency syndrome (AIDS) studied previously in our laboratory and 125 cases of high-grade NHL reported in the literature. The proliferative activity was higher in intermediate-grade HAL relative to non-AIDS NHL (24.0% v 10.4%; P = .03), and in high-grade HAL in comparison with NHLs of similar histology unassociated with HIV infection (24.8% v 19%), although the latter did not reach statistical significance. The number of mitoses per 10 high-power fields was found to correlate with the percentage of cells in S-phase (r = .68; P = .0004). Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields. When compared with non-AIDS NHLs of comparable grade, there was a trend toward a lower incidence of DNA aneuploidy in both intermediate- (25% v 56%) and high-grade (38.5% v 60%) HALs. The higher proliferative activity and lower incidence of DNA aneuploidy found in HAL relative to non-AIDS NHL of comparable histologic grade may represent differences in pathogenesis and may underlie the poor prognosis of HIV-associated NHL.
Collapse
Affiliation(s)
- S H McDunn
- Department of Medicine, Northwestern University Medical School, Chicago, IL 60611
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Von Roenn JH, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990; 17:13-6. [PMID: 2259923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Cachexia is a common problem in persons infected with the human immunodeficiency virus (HIV). Megestrol acetate, an agent used for the treatment of metastatic breast cancer, is associated with appetite stimulation and weight gain. To determine whether this drug might benefit HIV-positive patients, 22 such subjects (14 previously reported) were treated with oral megestrol acetate, beginning at a dose of 80 mg four times daily. All patients had lost at least 10% of their preillness weight prior to treatment; the median loss was 11.4 kg (range, 5.5 to 26.8). Preliminary data from patients observed during therapy from 2 to 72 weeks showed that 21 of the 22 patients gained weight; the average weight gain was 7.3 kg (range, -4.1 to 17.3). Three patients failed to gain weight on 320 mg per day of megestrol acetate; both appetite stimulation and weight gain were achieved with 460 mg per day in one and 640 mg per day in another. One patient continued to lose weight despite 480 mg per day megestrol acetate. The median time to peak weight during megestrol acetate treatment was 14 weeks. Seven patients returned to within 1 kg of their normal body weight. In three of the 22 patients treated, megestrol acetate and zidovudine were started simultaneously. For these three patients, weight gain was potentially due to the recognized weight gain associated with the initiation of zidovudine. For the remaining 18 patients, however, appetite stimulation and weight gain were a result of megestrol acetate. All patients tolerated the drug well. One patient developed a deep vein thrombosis. No patient developed peripheral edema or drug-related impotence. The appetite improvement and weight gain seen in this initial series are encouraging. The true effectiveness of megestrol acetate for HIV-related cachexia and the effects of treatment on quality of life are currently being assessed in a national prospective, randomized, double-blind, placebo-controlled trial.
Collapse
Affiliation(s)
- J H Von Roenn
- Department of Medicine, Northwestern University Medical School, Chicago, IL 60611
| | | | | |
Collapse
|
26
|
Von Roenn JH, Bonomi PD, Gale M, Anderson KM, Wolter JM, Economou SG. Sequential hormone therapy for advanced breast cancer. Semin Oncol 1988; 15:38-43. [PMID: 3368799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Sequential hormone therapy for advanced breast cancer can offer significant and prolonged disease control with minimal morbidity. Predictors of response to sequential hormone therapy have not previously been identified. Sixty postmenopausal women with advanced or recurrent breast cancer treated with sequential megestrol acetate and tamoxifen were evaluated to identify factors which predict response to sequential therapy. The response rate to first-line therapy was 28% (17/60). Forty-seven percent of patients who responded to the first therapy responded to the second (8/17). Four of 16 patients (25%) who failed the first hormone therapy responded to the second. The response rate to a second hormone therapy was 25% (15/60). Chi-square tests were used to test the association between a response to sequential hormonal therapy and prior chemotherapy, age at first hormone trial, number of sites of disease, dominant site of disease, sequence of hormonal therapy, second response on the basis of first response, presence of soft tissue disease or bone disease alone, and receptor value. A one-tailed Fisher exact probability test revealed that a greater proportion of receptor-positive patients exhibited positive responses to sequential hormonal therapies than did receptor-negative patients. All of the patients who responded to a second hormonal therapy were estrogen receptor (ER)- and progestogen receptor (PgR)-positive. Fisher exact probability tests revealed a statistically significant association between response to initial hormone therapy and response to a subsequent hormone trial. This study suggests that patients who fail their initial hormone trial should be considered for a second hormonal trial if they are ER- and PR-positive.
Collapse
Affiliation(s)
- J H Von Roenn
- Department of Medicine, Northwestern University, Chicago, IL 60611
| | | | | | | | | | | |
Collapse
|